Actualités thérapeutiques en hématologie.

Hematologic Neoplasms/therapy; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy; Multiple Myeloma/therapy

Abstract :

[en] This article focuses on recent advances in four important areas of hematology: aggressive lymphomas, allogeneic hematopoietic stem cell transplantation, multiple myeloma, and molecular therapy of cancer.

Disciplines :

Hematology

Author, co-author :

De Prijck, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Baron, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Beguin, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Bonnet, Christophe ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Willems, Evelyne ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Fillet, Georges ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Language :

French

Title :

Actualités thérapeutiques en hématologie.

Alternative titles :

[en] Current therapies in hematology

Publication date :

2007

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

5-6

Pages :

384-90

Peer reviewed :

Peer reviewed

Available on ORBi :

since 25 February 2009

Statistics

Number of views

259 (23 by ULiège)

Number of downloads

270 (7 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Harris NL, Jaffe ES, Stein H, et al. - A revised European-American Classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 1994, 84, 1361-1392.
Harris NL, Jaffe ES, Diebold J, et al. - World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues : report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol, 1999, 17, 3835-3849.
Schnitzer B. - Classification of lymphomas. CRC Crit Rev Clin Lab Sci, 1978, 9, 123-178.
A predictive model for aggressive non-Hodgkin's lymphoma. - The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med, 1993, 329, 987-994.
Fisher RI, Gaynor ER, Dahlberg S, et al. - Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med, 1993, 328, 1002-1006.
Tilly H, Lepage E, Coiffier B, et al. - Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood, 2003, 102, 4284-4289.
Feugier P, Van Hoof A, Sebban C, et al. - Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol, 2005, 23, 4117-4126.
Bonnet C, Fillet G, Mounier N, et al. - CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients : a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol, 2007, 25, 787-792.
Mounier N, Gisselbrecht C, Briere J, et al. - Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol, 2004, 22, 2826-2834.
Baron F, Storb R, Storer BE, et al. - Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol, 2006, 24, 4150-4157.
Juweid ME, Stroobants S, Hoekstra OS, et al. - Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol, 2007, 25, 571-578.
Jerusalem G, Beguin Y, Fassotte MF, et al. - Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood, 1999, 94, 429-433.
Jerusalem G, Depas G, De Leval L. - Rôle de la tomographie à émission de positons dans le bilan initial, l'évaluation thérapeutique et le suivi des patients atteints de lymphome. Rev Med Liège, 2007, 62, 42-46.
Weiden PL, Flournoy N, Thomas ED, et al. - Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med, 1979, 300, 1068-1073.
Baron F, Storb R. - Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders (Review). Molecular Therapy, 2006, 13, 26-41.
Baron F, Maris MB, Sandmaier BM, et al. - Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol, 2005, 23, 1993-2003.
McSweeney PA, Niederwieser D, Shizuru JA, et al. - Hematopoietic cell transplantation in older patients with hematologic malignancies : replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood, 2001, 97, 3390-3400.
Baron F, Baker JE, Storb R, et al. - Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after non-myeloablative conditioning. Blood, 2004, 104, 2254-2262.
Maris MB, Niederwieser D, Sandmaier BM, et al. - HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood, 2003, 102, 2021-2030.
Myeloma Trialists' Collaborative Group. - Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol, 1998, 16, 3832-3842.
Attal M, Harousseau J-L, Stoppa A-M, et al. - A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med, 1996, 335, 91-97.
Child JA, Morgan GJ, Davies FE, et al. - High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med, 2003, 348, 1875-1883.
Attal M, Harousseau JL, Facon T, et al. - Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med, 2003, 349, 2495-2502.
Bensinger WI. - Recent developments in hematopoietic stem cell transplantation for multiple myeloma (Review). Int J Hematol, 2003, 77, 232-238.
Maloney DG, Molina AJ, Sahebi F, et al. - Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood, 2003, 102, 3447-3454.
Bruno B, Rotta M, Patriarca F, et al. - A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med, 2007, 356, 1110-1120.
Cibeira MT, Rosinol L, Ramiro L, et al. - Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration. Eur J Haematol, 2006, 77, 486-492.
Jimenez-Zepeda VH, Dominguez-Martinez VJ. - Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma? Eur J Haematol, 2006, 77, 239-244.
Rajkumar SV, Hayman SR, Lacy MQ, et al. - Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood, 2005, 106, 4050-4053.
Richardson PG, Barlogie B, Berenson J, et al. - Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood, 2005, 106, 2977-2981.
Harousseau JL, Attal M, Leleu X, et al. - Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica, 2006, 91, 1498-1505.
Oehler VG, Radich JP, Storer B, et al. - Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. Biol Blood Marrow Transplant, 2005, 11, 85-92.
Guilhot F, Chastang C, Michallet M, et al. - Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med, 1997, 337, 223-229.
Druker BJ, Tamura S, Buchdunger E, et al. - Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of Bcr-ABL positive cells. Nat Med, 1996, 2, 561-566.
Druker BJ, Guilhot F, O'Brien SG, et al. - Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 2006, 355, 2408-2417.
Kantarjian H, Giles F, Wunderle L, et al. - Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med, 2006, 354, 2542-2551.
Guilhot F, Apperley J, Kim DW, et al. - Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood, 2007, sous presse.